Minimal Residual Disease Testing

Last Literature Review: October 2026 Last Update:

Medical Experts

Contributor

Karner

Kristin Hunt Karner, MD
Associate Professor (Clinical), University of Utah
Medical Director, Hematopathology and Molecular Oncology, ARUP Laboratories
Contributor

Ng

Picture of David P. Ng, MD, FCAP,
Associate Professor (Clinical), University of Utah
Medical Director, Hematopathology, Hematologic Flow Cytometry, Applied Artificial Intelligence and Bioinformatics, ARUP Laboratories

Minimal residual disease (MRD, also referred to as measurable residual disease) describes the small numbers of malignant cells that may persist after treatment and remain below the threshold of detection for conventional disease assessment. MRD is a strong predictor of relapse in many hematologic malignancies and has important implications for prognosis and treatment decision-making. MRD assessment is most established in hematologic malignancies, including leukemias and multiple myeloma, although MRD approaches are increasingly being investigated in solid tumors. Highly sensitive laboratory techniques can detect very small numbers of residual malignant cells and enable MRD assessment in clinical practice. Laboratory methods used for MRD assessment include polymerase chain reaction (PCR), massively parallel sequencing (MPS, also known as next generation sequencing [NGS]), and multiparameter flow cytometry.

Quick Answers for Clinicians

For which malignancies is minimal residual disease assessment recommended?

The National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and the European Hematology Association (EHA) recommend minimal residual disease (MRD) assessment for specific hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL, including pediatric ALL), chronic myeloid leukemia (CML), and multiple myeloma. -  MRD may also be assessed in some other hematologic malignancies. In chronic lymphocytic leukemia (CLL), the NCCN supports MRD assessment in routine practice to guide treatment duration.  In mantle cell lymphoma, MRD is incorporated into response-based treatment decision-making.  In myeloid/lymphoid neoplasms with eosinophilia, next generation sequencing-based MRD monitoring is an emerging adjunct for diagnosis and monitoring. 

What is the role of minimal residual disease testing in nonhematologic malignancies?

The role of minimal residual disease (MRD) assessment in patients with solid tumors (e.g., melanoma, lung cancer, and breast cancer) is currently being researched. Circulating tumor DNA (ctDNA)-based MRD assessment has supportive evidence for prognostic value, but its clinical utility for directing therapy is unclear. MRD testing is therefore not currently recommended to guide treatment in solid tumors. 

Indications for Testing

MRD testing may be used in hematologic malignancies to:

  • Assess treatment response and inform treatment decisions
  • Determine prognosis
  • Monitor remission and detect recurrence

Laboratory Testing

Testing Methods

MRD assessment is used across multiple hematologic malignancies, including acute lymphoblastic leukemia (ALL, including pediatric ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), lymphomas, and multiple myeloma. Recommended methodologies, specimen requirements, and clinical applications vary by disease. Clinicians should select MRD testing approaches that are supported by disease-specific guidelines and validated for the malignancy being assessed.

In multiple myeloma, the two most widely accepted methods for MRD assessment are next generation flow cytometry (NGF) and MPS. Both methodologies are incorporated into contemporary response criteria and clinical practice guidelines. For example, the International Myeloma Working Group (IMWG) recognizes both approaches as meeting requirements for high-sensitivity MRD detection, with sensitivity of at least 10-5.  The National Comprehensive Cancer Network (NCCN) has subsequently incorporated both methodologies into its guidance on MRD assessment. 

Although NGF and NGS use different technologies, they demonstrate high concordance and similar prognostic performance when performed on the same specimen.  Consequently, selection between methodologies is often driven less by differences in clinical validity than by practical considerations, including specimen requirements, laboratory availability, turnaround time, and disease-specific recommendations.

NGF refers to highly standardized flow cytometric approaches for MRD detection that use expanded antibody panels, acquisition of large numbers of cellular events, and standardized analytic methods to improve sensitivity as compared with traditional flow cytometry. Spectral flow technology further expands these capabilities by measuring the full emission profile of each fluorochrome and applying computational unmixing algorithms to resolve overlapping signals. This methodology enables high-parameter MRD assays to incorporate expanded marker panels within a single tube. 

The following table summarizes practical considerations that may influence selection of NGF- or NGS-based MRD testing in multiple myeloma.

Clinical Considerations When Ordering NGF- or NGS-Based MRD Testing in Multiple Myeloma
 NGFNGS
MRD detection targetIdentification and quantification of aberrant malignant cells based on immunophenotypeIdentification and quantification of disease-specific clonotypic sequences
Baseline sample requirementNot required (no pretreatment specimen needed)Typically requires an initial sample at diagnosis to identify clonotypic sequences for follow-up tracking
Analytic sensitivityTypically 10-5 to 10-6 based on the number of acquired eventsTypically up to 10-6
Turnaround timeRapid (24-48 hrs)Typically days to weeks
Sample requirementsFresh bone marrow aspirate; viable cells requiredFresh bone marrow aspirate or extracted DNA; less sensitive to transport delays
Hemodilution quality controlBuilt-in assessment of marrow quality using background populations (e.g., mast cells, erythroblasts, B-cell precursors), allowing recognition of hemodiluted samples that could otherwise yield false-negative resultsNo intrinsic assessment of hemodilution or marrow quality
Phenotypic insightSimultaneous quantitation of residual disease and characterization of targetable antigen expressionQuantitative tracking of disease-specific clonotype
Sources: Paiva, 2025 ; Zanwar, 2026 ; Costa, 2021 ; Marx, 2023 

Clinicians should consult disease-specific guidelines and laboratory test information when selecting an MRD assay, as preferred methodologies, specimen requirements, and reporting practices may differ among hematologic malignancies.

MRD Assessment in Specific Hematologic Malignancies

For more information about MRD testing and other laboratory testing in specific hematologic malignancies, refer to the following ARUP Consult topics:

ARUP Laboratory Tests

References